A5039315977- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- Radiomics and Machine Learning in Medical Imaging
- Infective Endocarditis Diagnosis and Management
- Advanced Radiotherapy Techniques
- Mycobacterium research and diagnosis
- Cancer Diagnosis and Treatment
- Metabolism, Diabetes, and Cancer
- Cardiovascular and Diving-Related Complications
- Enhanced Recovery After Surgery
- Surgical site infection prevention
- Stoma care and complications
- Colorectal Cancer Surgical Treatments
- Melanoma and MAPK Pathways
- Pancreatic function and diabetes
Utrecht University
2023-2025
University Medical Center Utrecht
2016-2025
Meander Medisch Centrum
2021
Wilhelmina Children's Hospital
2018
Current knowledge on prognostic biomarkers (especially BRAFV600E /RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based mCRC patients with proficient mismatch repair (pMMR) tumors. It uncertain whether these have the same value deficient (dMMR) This observational cohort study combined a population-based Dutch (2014-2019) and large French multicenter (2007-2017). All histologically proven dMMR tumor were included. In our real-world data of 707 patients, 438 treated first-line...
Abstract The treatment landscape for metastatic colorectal cancer (mCRC) has evolved into a continuum of care with an essential role biomarkers and molecular subgroups. Treatment guidelines are primarily based on trial results; however, populations outcomes differ from clinical practice. To support the interpretation results to assist in tailored patient counseling, we evaluated real‐world patterns according RAS/BRAF status. We included all patients diagnosed BRAF V600E ‐mutated mCRC...
Background Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). A significant proportion of show resistance, making identification determinants response crucial. Growing evidence supports role sex determining susceptibility to anticancer therapies, but data is lacking for MSI-H CRC. Methods In this real-world cohort comprising 624 mCRC receiving ICIs, we...
130 Background: Maintenance treatment with capecitabine and bevacizumab after capecitabine, oxaliplatin, therapy in metastatic colorectal cancer (mCRC) is shown to be effective observation as an acceptable alternative. Metastatic burden might aid shared decision-making the aim of this exploratory analysis assess prognostic predictive value number total volume metastases mCRC patients included CAIRO3 study. Methods: Patients study liver and/or lung were included. Every individual metastasis...
<h3>Importance</h3> Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients metastatic colorectal cancer (mCRC). However, the degree of implementation FOLFOXIRI-B in daily practice unknown. <h3>Objectives</h3> To evaluate current adoption rate mCRC investigate perspectives medical oncologists toward this option. <h3>Design, Setting, Participants</h3> This 1-week, multicenter,...
3589 Background: Approximately 10-15% of patients with metastatic colorectal cancer (mCRC) have BRAF V600E mutated tumors. Encorafenib plus cetuximab (EC) combination treatment was approved following the results randomized phase III BEACON trial and is currently recommended for all pretreated -mutant mCRC. Selection in controlled trials based on restrictive eligibility criteria often not representative patient population daily clinical practice. Complementary real-world effectiveness studies...
Mitral regurgitation (MR) grading by two-dimensional transthoracic echocardiography is challenging, but important to determine the best treatment strategy in patients with MR. Current guidelines advocate an integrative approach, although no recommendation provided on how do so. An easy-to-use index will be helpful for standardized and reproducible MR grading.Eleven echocardiographic parameters were retrospectively evaluated 145 moderate or severe Parameters scored positive negative MR, where...
Partial denervation of the wrist can benefit patients with chronic pain. A complication partial is loss proprioception and hypesthesia on dorsal side hand. Our aim to evaluate whether sensory branches posterior interosseous nerve could contribute sensation. The branching pattern was studied in 20 cadaveric hands. terminal reached metacarpophalangeal joints three specimens (15%), midshaft metacarpals carpometacarpal 11 (55%), scapholunate joint (15%). finding that reach indicates may...
Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors include a relatively new class of glucose-lowering drugs that reduce plasma glucose concentrations by inhibiting proximal tubular reabsorption in the kidney, while increasing its excretion urine. Recent large randomised controlled trials have demonstrated many these agents occurrence major adverse cardiovascular events, hospitalisation for heart failure, death and/or chronic kidney disease progression patients with and without type...
Cancer has become an important cause of death in solid organ transplant patients. The malignancies patients with transplants is multifactorial, but the use intensive immunosuppression regarded as factor. We describe spontaneous, complete regression colon cancer liver metastases, without initiation antitumor therapy, a patient after modulation immunosuppressants. Case Presentation. A 59-year-old female was admitted fever, general discomfort, and elevated enzymes. She had received single lung...
It is unclear whether curative-intent local therapy of metastases similar benefit for the biological distinct subgroup patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) compared proficient (pMMR) mCRC.In this nationwide study, recurrence-free (RFS) and overall survival (OS) were analyzed in dMMR versus pMMR mCRC who underwent treatment between 2015 2018. Subgroup analyses performed resection liver (CRLM) cytoreductive surgery ± hyperthermic intraperitoneal...
65 Background: Data on clinical treatment outcomes of systemic non-immunotherapy in patients with MSI-H mCRC are limited due to low incidence. Real world data can support the interpretation immunotherapy studies. Our aim is provide insight treated non-immunotherapy. Methods: We describe an observational cohort study real-world from Netherlands Cancer Registry during 2015-2018 (N=383) and trial-based three prospective phase III first-line trials: CAIRO, CAIRO2 CAIRO3 (N=54). investigated...